MDA-19

MDA-19

Legal status
Legal status	CA: Schedule II
Identifiers
IUPAC name (3Z)-N'-(1-hexyl-2-oxoindolin-3-ylidene)benzohydrazide
CAS Number	1048973-47-2
PubChem (CID)	25034599
ChemSpider	24689676
Chemical and physical data
Formula	C21H23N3O2
Molar mass	349.426 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(C1=CC=CC=C1)N/N=C(C2=CC=CC=C2N3CCCCCC)\C3=O
InChI InChI=1S/C21H23N3O2/c1-2-3-4-10-15-24-18-14-9-8-13-17(18)19(21(24)26)22-23-20(25)16-11-6-5-7-12-16/h5-9,11-14H,2-4,10,15H2,1H3,(H,23,25)/b22-19- Key:ZGQHMZCITJHYOW-QOCHGBHMSA-N
(what is this?)  (verify)

MDA-19 is a drug that acts as a potent and selective agonist for the cannabinoid receptor CB₂, with reasonable selectivity over the psychoactive CB₁ receptor, though with some variation between species. In animal studies it was effective for the treatment of neuropathic pain, but failed to produce cannabis-like behavioural effects.^[1][2]

See also

• AM-1221
• JTE 7-31
• JWH-019
• JWH-133
• N-(S)-Fenchyl-1-(2-morpholinoethyl)-7-methoxyindole-3-carboxamide

References

1. Diaz, Philippe; Xu, Jijun (2008). "Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the Treatment of Neuropathic Pain". J. Med. Chem. American Chemical Society. 51 (16): 4932–4947. doi:10.1021/jm8002203. PMID 18666769.
2. Xu, JJ; et al. (Jul 2010). "Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain". Anesthesia and Analgesia. 111 (1): 99–109. doi:10.1213/ANE.0b013e3181e0cdaf. PMC 3253719. PMID 20522703.